BioSpace News Archive

Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection of oral and oropharyngeal cancer, is proud to announce the launch of its newly redesigned website at http://www.vigilantbiosciences.com/ .

With a shared commitment to transforming the healthcare experience, The Ohio State University Wexner Medical Center, one of the nation’s top-ranked academic health centers, and One Medical, a leading national technology-powered primary care organization, will partner to deliver seamless coordinated care in Columbus and the central Ohio region.

The U.S. Department of Health and Human Services (HHS) today authorized pharmacists and pharmacist interns to order and administer COVID-19 vaccines that have been approved or licensed by the Food and Drug Administration (FDA) to all individuals age 3 or older.

September ushers in autumn, back-to-school and National Yoga Month. For yoga enthusiasts, it is the opportunity to further challenge the body’s strength, balance and posture.

PainReform Ltd. (NASDAQ:PRFX) today announced the closing on September 3, 2020 of its initial public offering of 2,500,000 units at a price of $8.00 per unit.

Leading researchers and physicians will present results from 10 clinical trials that focus on vascular interventional technology and treatment solutions on Friday, November 6, and Saturday, November 7, during the 18th annual VIVA (Vascular InterVentional Advances) conference, which will be held virtually.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will present a Company overview, as well as host virtual investor meetings, at the 2020 H.C. Wainwright Global Investment Conference

Clearside Biomedical, Inc. (NASDAQ:CLSD), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview at the Virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020 at 11:30 a.m. ET.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that the Company will present at H.C. Wainwright 22nd Annual Global Investment Conference,

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has commenced a public offering of up to 8,500,000 common shares (the “Common Shares”) of the Company (the “Offering”)